Aims: To evaluate the clinical and patient-reported outcomes and healthcare utilization and costs associated with patient-reported hypoglycaemia in US adults with type 2 diabetes (T2D) treated with basal insulin.
| INTRODUCTION
Diabetes is a chronic, progressive disease with an increasing prevalence worldwide 1 and in the United States. 2 The economic impact of diabetes is substantial, 3 with indirect costs of diabetes accounting for an estimated 36% of the total economic burden in North America. 4 Type 2 diabetes (T2D) is generally initially managed with lifestyle interventions and oral antidiabetes drugs (OADs), but many patients will eventually require insulin therapy to maintain good glycaemic control. 5, 6 Some anti-hyperglycaemic agents, such as sulphonylureas and exogenous insulin, can cause hypoglycaemia. 7 The psychological impact of hypoglycaemia can affect adherence to treatment, leading to missed or incorrect dosage, 8 with fear of hypoglycaemia and changes in self-care behaviour possibly compromising glycaemic control. 9 Research has also shown that, among patients with T2D in the United States, those who experienced hypoglycaemia were more likely to report having lower health-related quality of life (HRQoL) and higher rates of diabetes-related emergency room (ER) and physician visits. 10 For example, the Centers for Disease Control and Prevention report a total of 245 000 ER visits by adults with diabetes in the United States attributed to hypoglycaemia in 2014. 2 Hypoglycaemia-related medical expenditure and hospitalizations are associated with considerable costs and represent a major contribution to healthcare expenditures in the United States 11 and worldwide. 1 US patients who experience hypoglycaemia within 6 months of initiating basal insulin are also at an increased risk of basal insulin therapy discontinuation (68.1% of patients with hypoglycaemia within 6 months vs 53.9% of those without hypoglycaemia within 6 months) 12 and have significantly higher healthcare resource utilization and costs than those without hypoglycaemia ($13 662 vs $7506). 13 Hypoglycaemic symptoms and symptom severity also have an adverse effect on patients' ratings of their HRQoL. 14 It is therefore important to understand the burdens of hypoglycaemia from the patient perspective, including those of non-severe hypoglycaemic episodes that do not require assistance from a healthcare provider.
Studies of the burden of hypoglycaemia in T2D often use data captured from administrative claims via International Classification of Diseases Ninth Revision Clinical Modification (ICD-9-CM) codes. 11, 15 In such studies, the setting of the event is often used as a proxy for the severity of the event (ie, events requiring assistance from a healthcare professional, ER visits, or hospitalizations are considered the more severe events), 16 which may result in an underestimation of the true incidence and burden of hypoglycaemia, especially mild-tomoderate hypoglycaemia. 17, 18 Additionally, while a number of realworld database studies have reported costs associated with severe hypoglycaemia, 19, 20 few studies have investigated the direct or indirect burden of self-reported, non-severe hypoglycaemia that is managed by the patient themselves. This study was conducted to evaluate, from the patient's perspective, the clinical and patientreported outcomes, as well as healthcare utilization and costs, associated with patient-reported severe and non-severe hypoglycaemia in US patients with T2D using basal insulin AE OADs or rapid-acting/ premixed insulin.
| MATERIALS AND METHODS

| Study design
This was an observational, cross-sectional, survey-based study of adults (age ≥ 18 years) with T2D living in the United States and using basal insulin AE OADs or rapid-acting/premixed insulin, who reported having ever experienced hypoglycaemia. Data were obtained from the National Health and Wellness Survey (NHWS), an annual, patient-reported, online survey of demographically representative cross-sections of the adult populations of 10 countries, including the United States. 21, 22 All data are self-reported directly by participants. 
| Respondents
Potential respondents were identified through the general panel of Lightspeed Research, a partner organization of the NHWS that collects digital data from an online consumer panel. 23 Specific criteria for inclusion in the study were: age ≥ 18 years, self-reported diagnosis of T2D, use of a basal insulin with or without the concomitant use of OADs and/or rapid-acting/premixed insulin, and experience of at least 1 hypoglycaemic event in the past. Included patients were surveyed regarding their experience with hypoglycaemia in the preceding 3 months; non-severe hypoglycaemia refers to self-managed events, while severe hypoglycaemia events required third-party assistance. 24 It was possible for a respondent to complete >1 survey over the 3-year study period; in these instances, only the most recent data for a given respondent were kept.
| Study measures 2.3.1 | Demographics and comorbidities
To understand the disease burden associated with hypoglycaemia and evaluate differences between respondents reporting no hypoglycaemia, non-severe hypoglycaemia or severe hypoglycaemia in the preceding 3 months, respondents were compared based on demographics and health history using the variables listed in Appendix S1
in File S1.
| Health-related quality of life
The HRQoL of respondents was assessed using the Medical Out- to a mean of 50 for the general US population; a higher score indicates better health status. As the SF12-v2 provides the same metrics as the SF-36v2, data for all 3 years in the study can be pooled for subsequent analyses. 25 In addition to generating summary PCS and MCS scores, the SF-36v2 can also be used to generate health state utilities by applying the Short-Form 6 Dimensions (SF-6D) algorithm, which takes items from the domains of the SF-36v2. 27 Health utility scores from the SF-6D were derived from the SF-12v2 or SF-36v2
for the respective survey years. The SF-6D health utilities index has interval scoring properties and yields summary scores on a theoretical scale of 0 to 1. Higher scores indicate better health status.
| Work productivity
The work productivity of respondents was evaluated using the Work Productivity and Activity Impairment (WPAI) questionnaire (Table 1) . 28, 29 This is a 6-item validated instrument that consists of 4 metrics: absenteeism; presenteeism; overall work productivity loss; and activity impairment. Unemployed respondents were not included in evaluations of absenteeism, presenteeism or work productivity loss.
| Healthcare resource utilization
Healthcare resource utilization over the previous 6 months was assessed by patient recall of the number of overall provider visits, ER visits and hospitalizations (not necessarily diabetes-specific; Table 2 ).
| Healthcare costs
Both direct and indirect healthcare costs were calculated to give annualized estimates. Direct costs were based on the costs for an average physician visit, ER visit and hospitalization, determined using the 2012 Medical Expenditure Panel Survey. 30 For each respondent, the number of each type of visit was multiplied by 2, to project the annual number of visits, and then multiplied by its average cost.
Indirect costs were calculated by estimating wages/salaries for each respondent using 2012 data from the Bureau of Labor Statistics.
31
The number of hours missed because of health impairment (absenteeism), and the number of hours being unproductive while at work (presenteeism) because of health impairment during the previous week were each multiplied by the hourly wage rates to provide the total lost wages; these figures were then multiplied by the average number of work weeks in a year (ie, 50 weeks) to obtain annual indirect cost estimates.
| Statistical analyses
Bivariate differences were evaluated between respondents experiencing no, non-severe or severe hypoglycaemia for respondent demographics and characteristics, health status, healthcare resource use, and healthcare costs. For categorical variables, χ 2 tests were used to determine significant differences; one-way ANOVAs were used for continuous variables.
To analyse whether hypoglycaemia groups (ie, non-severe vs severe hypoglycaemia with no hypoglycaemia as the reference group for all comparisons) differ on health outcomes, a series of generalized linear models were used to test whether the adjusted means (accounting for covariates) of the outcomes differed between groups.
Generalized linear models with identity link functions were used for health status variables as they were normally distributed. Because of a pronounced skew, generalized linear models specifying a negative binomial distribution were used for work productivity and activity impairment, healthcare resource use and cost variables.
Covariates included all variables identified as significantly different between groups in the bivariate analyses, and those identified a 
Activity impairment
Percentage of impairment of regular daily activities because of one's health in the past 7 days, other than work at a job Abbreviation: WPAI, Work Productivity and Activity Impairment. The WPAI is a validated, 6-item, self-administered questionnaire that quantifies the influence of respondents' general health and disease symptom severity on their work productivity and regular activities during the previous 7 days. Scores from 4 domains are produced. Unemployed respondents were not included in evaluations of absenteeism, presenteeism, or work productivity loss; all respondents provided data for activity impairment; respondents in full-or part-time employment provided data for all 4 domains. a The term "your own medical condition" was used in the survey questions to ensure that all medical conditions were included, not only type 2 diabetes, and to exclude visits to accompany a friend or relative.
3 | RESULTS
| Study population
A total of 17 676 unique respondents with T2D were identified from the US NHWS, of whom 2423 met the criteria for inclusion in the study and completed the survey (Figure 1 ).
| Patient characteristics according to hypoglycaemia category
The demographics, health characteristics and diabetes characteristics of respondents are shown in Table 3 . Patients (N = 2423) were categorized into the categories "no hypoglycaemia in the past 3 months" (n = 938; 38.7%), "non-severe hypoglycaemia in the past 3 months" (n = 1335; 55.1%), and "severe hypoglycaemia in the past 3 months" (n = 150; 6.2% 
| Association of hypoglycaemia with outcomes (unadjusted)
Bivariate analyses were used to compare patients who experienced severe hypoglycaemia with those who experienced non-severe or no hypoglycaemia (Table S1 in File S1 
| Association of hypoglycaemia with outcomes (adjusted)
The results of multivariate analyses were consistent with unadjusted results after adjusting for covariates (Appendix S1). highlighting the significant impact of non-severe hypoglycaemia (Figure 2A ).
| Health-related quality of life
| Work productivity and activity impairment
Patients with severe hypoglycaemia had significantly greater impairment in overall work productivity (adjusted means 36.60% vs 21.30% and 18.01%; P < .05 for each comparison) and significantly greater impairment in activity (adjusted means 54.38% vs 41.13% and 38.81; P < .001 for each comparison) compared with patients with nonsevere or no hypoglycaemia. Work productivity and activity impairment were numerically, but not significantly, greater among patients with non-severe hypoglycaemia vs no hypoglycaemia ( Figure 2B ). Figure 2C ).
| Healthcare resource utilization
| Healthcare costs
As a result of greater work productivity impairment and resource use, *This category is not used in comparisons because its column proportion is equal to 0 or 1.
Patients with non-severe hypoglycaemia had greater annual indirect costs compared with those without hypoglycaemia (P = .039; Figure 2D ).
| DISCUSSION
In the present study, we aimed to evaluate the clinical and patient- (HAT) study. 37 These observations have been attributed to the inherent constraints of randomized controlled trials (eg, excluding subjects highly vulnerable to hypoglycaemia), which are likely to have resulted in an underestimation of the burden of hypoglycaemia in clinical practice. 37, 38 Additionally, patients with non-severe hypoglycaemia had significantly greater impairment in HRQoL, a higher number of traditional physician's visits and higher indirect costs than patients with no hypoglycaemia. The data from the present analysis support those from previous studies, which report significantly lower HRQoL, 18 and significantly higher economic burden 11, 18 in patients with T2D
experiencing hypoglycaemia compared with those without.
Data on NHWS participants with self-reported T2D have been collected in previous studies to assess the severity and frequency of hypoglycaemia episodes among patients treated with OADs only A survey of insulin-treated Japanese patients with either type 1 diabetes or T2D showed that experiencing a non-severe hypoglycaemic event can have a negative impact on diabetes management:
16% of patients with a daytime event and 19% of patients with a nocturnal event changed their insulin dose after the event. After a daytime event, 25% of patients reported a negative impact on their daily activities or work. After a nocturnal event, 34% reported a negative impact on sleep and 23% reported a negative impact on their functioning and well-being the following day. 40 Non-severe nocturnal hypoglycaemic events not only have serious consequences for patients, but also carry a considerable economic burden as a result of lost work productivity, doctor visits and medical care required because of falls or injuries. 41 The present study adds to the current knowledge base by describing clinical and patient-reported outcomes, healthcare utilization, and direct and indirect costs from a US population of patients with self-reported diabetes, but now focusing on those patients using basal insulin AE OADs or rapid-acting/premixed insulin. In line with previous real-world studies, the present study highlights the burden of hypoglycaemia on healthcare resource utilization, costs, and
HRQoL and shows that this burden increases with severity of hypoglycemia, but already significantly impacts patients at lower severity levels.
The present study has several strengths. Unlike most real-world studies that capture only the most severe events that result in a healthcare encounter, this study also captured patient reports of nonsevere hypoglycaemia. The patients' perspectives may highlight higher rates of hypoglycaemia than would be assumed by healthcare providers or than those which can be extracted from administrative claims or electronic medical record databases. Real-world data capturing the patient perspective are important to better understand the true burden of hypoglycaemia in the patient's life. Using data from surveys such as the NHWS provides a unique way of capturing the personal and social context of patients, including quality of life, work impairment, healthcare utilization and costs.
Some limitations of the present study should also be mentioned.
Because of the self-reported nature of this study, diabetes diagnosis and other variables could not be verified from patients' medical charts or other objective data. The validity of the study may be reduced because self-reported data are subject to recall bias, such as recalling the number of doctor visits, ER visits and hospitalizations.
However, the timeframe of the healthcare resource use variables in the study required recall for the past 6 months, which is within the timeframes of other large-scale cross-sectional surveys. by the NHWS database, healthcare resource utilization data could not be definitively attributed to diabetes. However, comorbidities (ie, CCI) were controlled for in the multivariable analyses to better estimate the association between resource use and diabetes/hypoglycaemia. Finally, while the NHWS is designed to be representative of the general US adult population, it is possible that the diabetes subpopulation may have been selectively underrepresented, because of age and/or technology-related limitations; the sample is likely to favour younger, healthier adults (see Table 3 for detailed demographic and clinical patient characteristics), and respondents without Internet or computer access were not represented in the current sample. The study may have picked up a population which was at a higher risk of hypoglycaemia by including only patients who reported having experienced hypoglycaemia in the past. The results may not be generalizable to the wider population.
In conclusion, the results of the present study suggest that, of US patients with T2D using basal insulin AE OADs or rapid-acting/ premixed insulin, those experiencing severe hypoglycaemia had greater impairment of activity and work productivity, utilized healthcare resources to a greater extent, incurred higher associated costs than those with non-severe or no hypoglycaemia, and reported a negative impact on HRQoL outcomes. The study also highlights the burden of non-severe hypoglycaemia, in particular on patients'
HRQoL, the number of outpatient visits, and indirect healthcare costs. Reducing the incidence and severity of hypoglycaemia could lead to clinically meaningful improvements in HRQoL, and reduce healthcare utilization and associated costs. These findings highlight a need to reduce hypoglycaemia and minimize its negative effects in patients with T2D on insulin therapy. 
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